The Efficacy of Recombinant Platelet-Derived Growth Factor on Beta-Tricalcium Phosphate to Regenerate Femoral Critical Sized Segmental Defects: Longitudinal<i>In Vivo</i>Micro-CT Study in a Rat Model

Badwelan, Mohammed; Alkindi, Mohammed; Ramalingam, Sundar; Nooh, Nasser; Hezaimi, Khalid Al

doi:10.1080/08941939.2018.1519048

Cited by 11 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the manufacturer (Kasios SAS) and importer (B.IMTECH, Yongin, Korea) advertised as 99% of β-TCP. Many studies and FDA 510(k) also represented as β-TCP17575859606162636465. It was received human study level III by successful histologic and clinical result comparing Xenograft (BonePlus-xs; Integros, Adana, Turkey) in sinus lift57.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Dental alloplastic bone substitutes currently available in Korea

Hong

Lee

et al. 2019

J Korean Assoc Oral Maxillofac Surg

View full text Add to dashboard Cite

As dental implant surgery and bone grafts were widely operated in Korean dentist, many bone substitutes are commercially available, currently. For commercially used in Korea, all bone substitutes are firstly evaluated by the Ministry of Health and Welfare (MOHW) for safety and efficacy of the product. After being priced, classified, and registration by the Health Insurance Review and Assessment Service (HIRA), the post-application management is obligatory for the manufacturer (or representative importer) to receive a certificate of Good Manufacturing Practice by Ministry of Food and Drug Safety. Currently, bone substitutes are broadly classified into C group (bone union and fracture fixation), T group (human tissue), L group (general and dental material) and non-insurance material group in MOHW notification No. 2018-248. Among them, bone substitutes classified as dental materials (L7) are divided as xenograft and alloplastic bone graft. The purpose of this paper is to analyze alloplastic bone substitutes of 37 products in MOHW notification No. 2018-248 and to evaluate the reference level based on the ISI Web of Knowledge, PubMed, EMBASE (1980–2019), Cochrane Database, and Google Scholar using the criteria of registered or trademarked product name.

show abstract

Section: Resultsmentioning

confidence: 99%

“…It was received human study level III by successful histologic and clinical result comparing Xenograft (BonePlus-xs; Integros, Adana, Turkey) in sinus lift57. Animal, in vivo , and in vitro studies for osteoconductivity5859606162636465.…”

Section: Resultsmentioning

confidence: 99%

Dental alloplastic bone substitutes currently available in Korea

Hong

Lee

et al. 2019

J Korean Assoc Oral Maxillofac Surg

View full text Add to dashboard Cite

show abstract

“…The MPM kit consisted of four 9-mL tubes without anticoagulant, one 9-mL preparation tube, two sterile containers, 0.5 cc β-TCP bone graft, and a 6-mL injection syringe. Growth factors are susceptible to β-TCP granules and show satisfactory effects on tissue regeneration [54,55]. Xenogeneic bone graft materials resorb slowly and growth factors are not affinitive to xenografts.…”

Section: Discussionmentioning

confidence: 99%

Histologic, Histomorphometric, and Clinical Analysis of the Effects of Growth Factors in a Fibrin Network Used in Maxillary Sinus Augmentation

Çinar

Gültekin

Saglanmak

et al. 2020

IJERPH

View full text Add to dashboard Cite

This randomized controlled clinical trial evaluated the effect of mineralized plasmatic matrix (MPM), comprised of synthetic graft and platelet concentrates, on new bone formation and volume stability over time in maxillary sinus lifting (MSL). Unilateral MSL was performed in 20 patients with either beta-tricalcium phosphate (β-TCP) or MPM grafts (10 sinuses each). Six months postsurgery, specimens were obtained with a trephine bur prior to implant placement in 39 cases. Volumetric changes in sinus augmentation were analyzed between 1 week (T-I) and 6 months (T-II) postsurgery. Histomorphometric and histological analyses of biopsy samples revealed mean new bone percentages of 35.40% ± 9.09% and 26.92% ± 7.26% and residual graft particle areas of 23.13% ± 6.16% and 32.25% ± 8.48% in the MPM and β-TCP groups, respectively (p < 0.05). The mean soft-tissue areas in the MPM and β-TCP groups were 41.48% ± 8.41% and 40.83% ± 8.86%, respectively (p > 0.05). Graft reductions between baseline and 6-months postprocedure in the β-TCP and MPM groups were 17.12% ± 13.55% and 14.41% ± 12.87%, respectively, with significant graft volume reduction observed in both groups (p < 0.05) while there is no significant difference between MPM and β-TCP groups (p > 0.05). Thus, MPM, representing growth factors in a fibrin network, increases new bone formation and has acceptable volume stability in MSL procedures

show abstract

“…This reveals that a relatively select group of growth factors in the overall setting of bone tissue engineering has been investigated in spinal fusion. For example, growth factors like stromal-derived growth factor 1 (SDF-1) and platelet derived growth factor (PDGF), both of which have been studied in the setting of regenerating critical sized bone defects[63,64], are notably absent in the preclinical spine fusion literature. While tissue engineering for spinal fusion is unique from other areas of bone tissue engineering in that the fusion site may be in motion during the fusion process, our review suggests potential new research strategies regarding the investigation of currently unexplored growth factors ( e.g ., SDF-1 and PDGF) for spinal fusion.…”

Section: Discussionmentioning

confidence: 99%

Investigational growth factors utilized in animal models of spinal fusion: Systematic review

Cottrill¹,

Ahmed²,

Lessing³

et al. 2019

WJO

View full text Add to dashboard Cite

BACKGROUND Over 400000 Americans annually undergo spinal fusion surgeries, yet up to 40% of these procedures result in pseudoarthrosis even with iliac crest autograft, the current “gold standard” treatment. Tissue engineering has the potential to solve this problem via the creation of bone grafts involving bone-promoting growth factors ( e.g ., bone morphogenetic protein 2). A broad assessment of experimental growth factors is important to inform future work and clinical potential in this area. To date, however, no study has systematically reviewed the investigational growth factors utilized in preclinical animal models of spinal fusion. AIM To review all published studies assessing investigational growth factors for spinal fusion in animal models and identify promising agents for translation. METHODS We conducted a systematic review of the literature using PubMed, Embase, Cochrane Library, and Web of Science databases with searches run on May 29 th , 2018. The search query was designed to include all non-human, preclinical animal models of spinal fusion reported in the literature without a timespan limit. Extracted data for each model included surgical approach, level of fusion, animal species and breed, animal age and sex, and any other relevant characteristics. The dosages/sizes of all implant materials, spinal fusion rates, and follow-up time points were recorded. The data were analyzed and the results reported in tables and text. PRISMA guidelines were followed for this systematic review. RESULTS Twenty-six articles were included in this study, comprising 14 experimental growth factors: AB204 ( n = 1); angiopoietin 1 ( n = 1); calcitonin ( n = 3); erythropoietin ( n = 1); basic fibroblast growth factor ( n = 1); growth differentiation factor 5 ( n = 4), combined insulin-like growth factor 1 + transforming growth factor beta ( n = 4); insulin ( n = 1); NELL-1 ( n = 5); noggin ( n = 1); P-15 ( n = 1); peptide B2A ( n = 2); and secreted phosphoprotein 24 ( n = 1). The fusion rates of the current gold standard treatment (autologous iliac crest bone graft, ICBG) and the leading clinically used growth factor (BMP-2) ranged widely in the included studies, from 0-100% for ICBG and from 13%-100% for BMP-2. Among the identified growth factors, calcitonin, GDF-5, NELL-1, and P-15 resulted in fusion rates of 100% in some cases. In addition, six growth factors - AB204, angiopoietin 1, GDF-5, insulin, NELL-1, and peptide B2A - resulted in significantly enhanced fusion rates compared to ICBG, BMP...

show abstract

The Efficacy of Recombinant Platelet-Derived Growth Factor on Beta-Tricalcium Phosphate to Regenerate Femoral Critical Sized Segmental Defects: LongitudinalIn VivoMicro-CT Study in a Rat Model

Cited by 11 publications

References 42 publications

Dental alloplastic bone substitutes currently available in Korea

Dental alloplastic bone substitutes currently available in Korea

Histologic, Histomorphometric, and Clinical Analysis of the Effects of Growth Factors in a Fibrin Network Used in Maxillary Sinus Augmentation

Investigational growth factors utilized in animal models of spinal fusion: Systematic review

Contact Info

Product

Resources

About